Stimulation has to start nitric oxide before any PDE5 tablet works

No nitric oxide, no useful corporal flow

Sildenafil, tadalafil, and vardenafil slow cGMP breakdown. They do not start nitric oxide. A tablet on a quiet couch does nothing useful. That is the pathway, not a slogan.

Nitrates and riociguat stay a hard stop

The screen in front of every PDE5 moiety is organic nitrates and riociguat. An ANDA generic does not invent a fourth enzyme. An unlicensed pack is a safety problem, not a new mechanism.

Erection Is Blood Flow Physics, Not a Mood Switch

Patients describe erection as desire flipping a switch. In the corpus cavernosum it is a hemodynamic balance: arterial inflow up, venous outflow trapped by expanding sinusoids against the tunica albuginea.

Erectile dysfunction means repeated failure to reach or hold that state for satisfactory sex. Prevalence climbs with age and stacks with diabetes, hypertension, dyslipidemia, and smoking because penile arteries are end-organ vessels that fail early when endothelium fails.

Oral PDE5 inhibitors became first-line after sildenafil's 1998 approval because they hit a validated enzymatic step instead of injecting vasodilator into corpora. They help many men with mild-to-moderate vasculogenic disease and fail predictably when nitric oxide delivery or veno-occlusive mechanics are wrecked.

Prescribing well means stating capability and limits upfront. The drug amplifies a signal stimulation must start. It does not restore libido alone, does not reverse major nerve transection overnight, and does not replace glucose, pressure, or lipid control on injured endothelium.

Label check: before the first script, stratify cardiovascular risk — sex raises myocardial oxygen demand like moderate exertion. Unstable angina, decompensated heart failure, and poorly controlled arrhythmias mean defer activity and defer PDE5 until stabilized.

We focus here on pharmacology linking pathophysiology to sildenafil, tadalafil, and vardenafil. Intracavernosal alprostadil, vacuum devices, and prosthesis matter when oral trials fail but sit outside today's scope.

Telehealth widened access and sometimes shortened cardiac history. Mechanism, contraindications, and interactions apply whether the encounter was in person or on a phone. Priapism beyond four hours is urologic emergency for any PDE5 agent — generic or not.

Label check: a structured history — duration, morning erections, libido, partner context, med list — takes minutes and prevents misprescribing when testosterone or depression treatment is the real need. Princeton Consensus still asks whether heart disease is stable enough for activity before you pick an agent.

Angina trials that noticed penile erection as side effect redirected an entire drug class — a useful teaching story about serendipity, but not a reason to skip workup when a fifty-year-old with new ED also has exertional chest pressure.

ED visits are vascular triage opportunities. The penis and the coronaries share risk. Use the prescription moment for smoking, lipids, glucose, and activity — not only for tablet selection.

Men who describe sudden complete loss with preserved morning erections deserve a psychogenic and relational workup before you chase higher PDE5 doses — the pathway can be intact while anxiety blocks use.

Priapism beyond four hours is a urology emergency regardless of agent; generic status does not soften that instruction.

How We Define ED — and What the Numbers Imply

NIH consensus language defines erectile dysfunction as persistent inability to achieve or maintain erection sufficient for satisfactory sexual performance. Surveys place moderate-to-complete dysfunction in roughly fifteen to twenty-five percent of men forty to seventy, higher in diabetes and post-MI cohorts.

Pattern and tempo separate organic from psychogenic threads. Sudden situational loss with intact morning erections and libido points to performance anxiety or relationship stress. Gradual decline with vascular risk factors points to endothelial and arterial insufficiency. Mixed cases dominate; fixing blood pressure does not erase learned failure without addressing cognition and partner dynamics.

Longitudinal data link baseline erectile severity to later cardiovascular events — the history is vascular triage, not a checkout-line prescription. Massachusetts Male Aging Study and successors reframed ED as chronic medical disease.

IIEF-5 and full domain scoring, plus Erection Hardness Score in trials, give reproducible anchors. A four-point erectile function domain shift often marks clinically meaningful response in registration studies; reuse the same tools at follow-up.

Organic buckets: vasculogenic endothelial dysfunction, neurogenic injury after prostatectomy or spinal disease, hypogonadism cutting libido and NOS expression, iatrogenic causes from SSRIs, thiazides, antiandrogens. Review meds before dose escalation.

Psychogenic and relational factors drive sympathetic outflow during attempts; combined sex therapy and PDE5 beat either alone in mixed presentations. Partner distress is under-measured and clinically real.

Classification sets expectations: non-nerve-sparing prostatectomy responds less to oral monotherapy than mild vasculogenic ED in a newly diagnosed hypertensive whose endothelium may improve with risk-factor control.

Label check: age is not etiology. An eighty-year-old with new failure and claudication needs vascular workup, not dismissal as normal aging. IIEF-5 scores at or below twenty-one flag dysfunction in many epidemiologic cuts; borderline scores deserve repeat assessment with partner input.

Depression screens belong in mixed cases — treating mood sometimes restores function without PDE5. Shift work and sleep debt hit libido centrally; sleep hygiene may complement pills in occupational cohorts.

Label check: cKD and dialysis shift protein binding and clearance differently by agent — monograph dose tables beat class generalizations.

Domains beyond erectile function on IIEF — orgasm, desire, satisfaction — help when history is ambiguous between low libido and failed rigidity.

Work-related travel through time zones does not change PK but changes sleep and libido — ask about shift work before blaming oral therapy.

Label check: partner-specific situational failure with intact morning erections often needs relational or behavioral referral, not a third PDE5 molecule in the same month.

Corporal Anatomy: Inflow, Trapping, and Detumescence

Paired corpus cavernosum bodies hold endothelial-lined sinusoids and trabecular smooth muscle inside the tunica albuginea. Rigidity needs both increased inflow and effective venous trapping.

Flaccidity reflects sympathetic tone keeping trabecular and helicine arteries contracted with minimal flow. Sexual stimulation fires parasympathetic and nonadrenergic noncholinergic fibers that release nitric oxide at nerve terminals and endothelium.

Nitric oxide diffuses into smooth muscle, activates soluble guanylate cyclase, converts GTP to cyclic GMP. Elevated cGMP activates protein kinase G, drops intracellular calcium via sequestration and hyperpolarization, relaxes sinusoids and arteries.

Arterial inflow can exceed one hundred milliliters per minute at full rigidity. Expanding sinusoids compress subtunical venules against the tunica — the veno-occlusive mechanism that turns inflow into sustained hardness. Breakdown anywhere yields clinical ED.

Detumescence follows PDE degradation of cGMP, restored sympathetic tone, smooth muscle contraction after orgasm or withdrawn stimulation. Ischiocavernosus contraction adds rigidity beyond passive hemodynamics in some men.

Testosterone modulates libido and supports NOS expression; check testosterone when desire is low despite intact reflexogenic responses on nocturnal testing.

This sequence is why PDE5 drugs are downstream amplifiers: no upstream nitric oxide from arousal, no clinically meaningful erection from blocking degradation alone.

Endothelial dysfunction cuts nitric oxide bioavailability before cavernosal fibrosis appears in aging men. Animal data tie androgen status to PDE5 expression — hypogonism workup belongs when libido is absent despite reflexogenic erections.

Veno-occlusive failure — venous leak — gives rigidity that fades fast despite initial tumescence. Men say they get hard then lose it; cGMP-targeted pills may not fix outflow anatomy without local therapy.

Performance anxiety spikes sympathetic tone during attempts and can override pharmacologically enhanced cGMP — situational failure with adequate drug exposure and intact anatomy.

Nocturnal penile tumescence testing is rarely needed in primary care but preserved morning erections with situational failure strongly suggest a psychogenic layer — address it before triple PDE5 trials.

Radical prostatectomy nerve-sparing status predicts oral response better than agent brand — set timelines in months, not weeks, when counseling post-surgical men.

NO–cGMP Signaling and Where PDE5 Fits

PDE5 is the dominant cyclic nucleotide phosphodiesterase in corpus cavernosum. It ends the erectile signal by hydrolyzing cGMP to inactive 5′-GMP.

Neuronal and endothelial NOS isoforms feed the nitric oxide pool during stimulation. Pelvic surgery, diabetic neuropathy, and endothelial injury shrink the substrate PDE5 inhibitors act on — explaining response heterogeneity bench potency never predicts.

Label check: soluble guanylate cyclase can be stimulated by riociguat, raising cGMP synthesis while PDE5 inhibitors block breakdown. Dual pathway overlap is absolute contraindication — cGMP rises without compensatory control.

Sildenafil, tadalafil, and vardenafil bind the PDE5 catalytic domain with high affinity during nitric oxide windows. Selectivity versus other PDE families drives class adverse effects: PDE6 cross-reactivity and visual symptoms; PDE11 cross-reactivity invoked in tadalafil back pain though debate continues.

These agents amplify; they do not initiate. That separates oral PDE5 therapy from intracavernosal alprostadil, which relaxes smooth muscle through prostaglandin routes without needing upstream nitric oxide.

Pulmonary vasculature uses the same cGMP pathway — lower-dose sildenafil regimens for PAH use different strengths and schedules than ED products. Household confusion between indications causes dosing disasters.

Structural studies of PDE5 with bound inhibitors show conformational states affecting dissociation kinetics; sildenafil functional duration tracks relatively short half-life, tadalafil decouples plasma persistence from perceived window length.

Corpus cavernosum expresses PDE5 abundantly versus other isoforms — validating the target. PDE1 in vascular smooth muscle and PDE11 in testis and prostate explain some class-wide effects beyond penile tissue.

Both nNOS at cavernous nerve terminals and eNOS in penile vessels contribute during stimulation. Surgery, diabetes, and smoking shrink the pool inhibitors need.

Label check: soluble guanylate cyclase stimulators beyond riociguat are not part of routine ED polypharmacy today, but pathway literacy explains why stacking any cGMP-raising drug with PDE5 blockade is hemodynamically reckless.

Where the Pathway Breaks in Clinical ED

Label check: organic erectile dysfunction usually means failure of nitric oxide availability, smooth muscle relaxation, arterial inflow, or veno-occlusive trapping — alone or in combination.

Endothelial dysfunction in diabetes, hypertension, hyperlipidemia, and smoking lowers nitric oxide and baseline cGMP, capping PDE5 benefit regardless of tablet potency.

Cavernous nerve injury from radical prostatectomy disrupts neural nitric oxide; early rehab protocols use PDE5 though success stays lower than uncomplicated vasculogenic cases.

Venous leak from tunica or trabecular disease prevents occlusion despite decent inflow — oral PDE5 often disappoints until injection, vacuum, or surgery.

Label check: hypogonism cuts libido and may blunt NOS expression; symptomatic low testosterone may need replacement alongside PDE5 for full benefit.

Performance anxiety raises sympathetic outflow; cognition and partner work complement pills.

Pelvic radiation, metabolic syndrome, CKD, and saddle neuropathy add insults. Med review catches iatrogenic contributors before infinite dose escalation.

Post-prostatectomy recovery can show nerve regeneration over months — early failure alone does not mean wrong drug.

Metabolic syndrome stacks insulin resistance, dyslipidemia, and hypertension against erectile hemodynamics synergistically. Radiation damages cavernous vessels and nerves with delayed onset.

Thiazides and antiandrogens belong on the substitution list before you blame PDE5 class failure.

Label check: central sympathetic overactivity from anxiety opposes parasympathetic nitric oxide release — brief CBT can address that layer without abandoning pharmacotherapy.

Label check: fibrosis of corpora cavernosum in long-standing diabetes or post-radiation disease limits smooth muscle compliance — PDE5 cannot fix structural stiffening; second-line local therapy enters earlier.

Medication-induced ED from spironolactone, opioids, and 5-alpha reductase inhibitors deserves substitution review — silent PDE5 escalation masks iatrogenic cause.

Class Pharmacology and Choosing Among Three Agents

Sildenafil, tadalafil, and vardenafil share selective PDE5 inhibition but diverge in PK, food interactions, and labeled regimens — distinctions that drive selection more than bench IC50 rankings.

Class contraindications: organic nitrates, nitric oxide donors, guanylate cyclase stimulators — combined cGMP elevation causes life-threatening hypotension. Alpha-blockers need stable dosing, separation, and blood pressure monitoring with BPH co-treatment.

Common adverse effects are vasodilation: headache, flushing, dyspepsia, nasal congestion. Visual changes tie to PDE6, especially with sildenafil. Back pain and myalgia cluster with tadalafil in some analyses.

Sildenafil peaks near sixty minutes fasted with three-to-five-hour half-life; high-fat meals delay absorption. Vardenafil mirrors food sensitivity. Tadalafil shows minimal food effect and ~17.5-hour half-life enabling daily low-dose ED and BPH regimens.

Daily tadalafil gives continuous partial PDE5 inhibition unlike PRN use; strengths and indications are not interchangeable at the pharmacy. No documented biochemical tachyphylaxis — waning effect over years usually tracks worsening vascular disease.

Avanafil adds faster onset in some markets with shared contraindications. CYP3A4 dominates interactions; potent inhibitors force label dose caps.

Bench potency favors vardenafil on paper; real-world choice follows tolerance, meals, duration preference, and comorbid meds — not lecture-slide IC50 order.

Intracavernosal alprostadil bypasses nitric oxide locally when optimized oral trials fail.

Label check: renal and hepatic impairment prolong exposure differently by agent; Child-Pugh caps live in individual labels. Sildenafil protein binding exceeds ninety-six percent — dialytic removal negligible, creatinine clearance tables guide adjustment.

Daily tadalafil for BPH LUTS shares mechanism with ED dosing but different trial instruments — IPSS gains do not automatically predict erectile function when you pick dose for mixed complaints.

Retinitis pigmentosa carries relative contraindication class-wide because PDE6 is the photoreceptor isoform affected.

Renal transplant recipients on calcineurin inhibitors need CYP3A4 review when adding any PDE5 agent — exposure shifts when antifungal prophylaxis starts.

Label check: daily tadalafil for LUTS does not replace 5-alpha reductase inhibitor when prostate volume is large and PSA rises — combination remains common in urology practice.

Trial Endpoints and Response Rates Worth Quoting Accurately

Label check: registration programs shared randomized double-blind placebo-controlled designs with IIEF erectile function domain and diary-documented successful intercourse endpoints.

Goldstein et al. 1998 NEJM sildenafil trial showed dose-dependent IIEF gains at twenty-five, fifty, and one hundred milligrams over twenty-four weeks. Tadalafil PRN and daily trials showed domain gains; daily five milligrams improved IPSS in BPH studies.

Teaching trial literacy: intention-to-treat includes men who never took the pill — real-world success requires adherence counseling, not just prescription strength.

Vardenafil trials reported similar effect sizes in general populations. Successful intercourse rates exceed seventy percent at optimized doses in mild-to-moderate disease but fall toward fifty to sixty percent in diabetes and twenty-five to forty percent early after non-nerve-sparing prostatectomy in pooled summaries — numbers that belong in pre-procedure counseling.

Open-label extensions support years of use without pharmacologic tolerance. Placebo arms improve through regression and psychogenic components — adequate dose trials on multiple occasions matter before labeling nonresponse.

Clinically meaningful questionnaire change often aligns with four-point domain shifts used as regulatory responder definitions. Reassess at eight to twelve weeks at optimized dose.

Trials excluded unstable cardiovascular disease and nitrate users; real-world panels carry more comorbidity, modestly trimming average benefit while contraindications stay fixed.

Crossover designs allowed preference assessment after blinded periods. Meta-analyses at equipotent doses show similar odds ratios across agents — class effect with convenience differences.

Diary successful intercourse correlates with patient-centered outcomes better than lab hemodynamics from early physiology studies. Teach intention-to-treat and why placebo improves.

Two- to three-year extensions report sustained benefit in responders without PDE5 downregulation — loss of effect tracks diabetes and atherosclerosis progression more often than receptor desensitization.

Strict trial definitions required penetration and completion; partial rigidity without penetration counted as failure — stricter than casual patient language about getting hard.

Heart Risk Before Bedroom Risk

Sexual activity stresses myocardial oxygen demand like moderate exertion. Princeton Consensus and successors integrate ED evaluation with cardiac stratification.

Label check: active unstable angina, decompensated heart failure, or uncontrolled hypertension — defer PDE5 until stabilized. Recent MI or stroke needs individualized cardiology guidance on safe activity resumption before prescribing.

Label check: stable angina on medical therapy may permit PDE5 when exercise tolerance is adequate and nitrates are not required for symptoms. Nitrate co-prescription stays absolute contraindication regardless of stability.

PDE5 inhibitors modestly lower blood pressure in normotensive men; with antihypertensives usually tolerable. Orthostatic symptoms mean dose adjustment and alpha-blocker timing review.

ED may precede symptomatic coronary disease by years — use the visit for vascular risk counseling, not only dispensing.

Label check: emergency departments need last PDE5 dose before nitrate consideration; washout intervals differ by half-life though avoidance remains preferred.

Stable angina patients who achieve four METs without symptoms may resume activity and PDE5 when cardiology agrees. Treadmill testing remains practical when history is ambiguous.

Multiple risk factors without angina still warrant pressure, lipid, and glucose optimization — the penis is an end-organ barometer.

Document activity clearance in the chart when you prescribe after cardiac history — medicolegal clarity if chest pain occurs during intercourse.

Recent stroke or MI requires individualized cardiology input — PDE5 is not automatically forbidden forever; activity capacity is the gate, not calendar time alone.

Label check: alpha-blocker co-therapy for BPH adds orthostatic risk with any PDE5 agent — first co-dose week deserves seated and standing vitals when feasible.

First-Line Sequence That Actually Gets Used

AUA and ISSM guidelines anchor lifestyle modification, comorbidity control, and psychosexual counseling before or alongside pharmacotherapy.

Label check: weight loss, exercise, smoking cessation, and sleep apnea treatment improve endothelium and may raise PDE5 response without higher doses. Glucose and pressure targets hit upstream vasculogenic drivers.

Trial adequate PDE5 dose on several attempts with correct meal timing before declaring oral failure. Under-dosing and post-steak sildenafil are fixable errors, not class failure.

Agent selection weighs duration, food independence, daily versus PRN preference, BPH co-treatment, and CYP3A4 inhibitors. Molecule switch is therapeutic experiment, not generic substitution.

Second line: intracavernosal or intraurethral alprostadil, vacuum devices, prosthesis when optimized oral fails. Refer refractory or complex post-surgical cases to urology or sexual medicine.

Testosterone replacement belongs in symptomatic hypogonadal men; PDE5 monotherapy underperforms when libido and NOS support are deficient.

Couples therapy and brief sex counseling help mixed psychogenic-organic cases. Vacuum devices preserve length when PDE5 is contraindicated by concurrent nitrate therapy for stable angina.

Label check: referral timing: months of silent dose escalation without partner talk delays effective second-line care. Document attempt count at optimized dose with food corrections before writing oral therapy failed.

Penile Doppler and specialized vascular testing sit second tier when history suggests venous leak or arterial insufficiency out of proportion to expected PDE5 response. Most primary care paths do not need imaging before standardized oral trial.

Shared decision-making should include partner views on spontaneity versus planning — half-life and food rules affect couples as much as IIEF points.

When oral therapy fails, ask whether stimulation, meals, dose, nitrates, CYP3A4 drugs, and pharmacy source were optimized — that sequence teaches pharmacology better than reflexive dose doubling.

Hypogonism workup belongs when libido is absent despite trials at adequate dose — PDE5 cannot manufacture desire, only support rigidity once arousal pathways engage.

Selective serotonin reuptake inhibitors blunt erectile function through central and peripheral mechanisms; dose escalation without addressing the antidepressant plan frustrates everyone.

Bicycle saddle neuropathy is niche but real in couriers and long-distance cyclists — worth one history question before you label oral class failure.

International Index of Erectile Function change at follow-up gives you documentation payers and urology colleagues actually read — use it instead of vague better or worse notes.

Subgroups, Teaching Points, and Label Hygiene

Renal and hepatic impairment prolong exposure for several agents; label caps guide adjustment. Older adults may need lower starts though age alone is not contraindication when cardiovascular status permits activity.

Diabetes combines endothelial dysfunction and neuropathy; higher doses or alternate agents may follow optimized glycemic control. Post-prostatectomy patients need early rehab and realistic nerve recovery timelines.

Spinal cord injury with preserved sacral reflexes may retain reflexogenic erections augmentable by PDE5 when partner stimulation triggers local nitric oxide despite absent psychogenic erections in complete lesions.

Depression and ED interact bidirectionally; SSRIs may worsen function — integrate mental health and urology instead of silent escalation.

Female partners ask about indirect benefit; PDE5 lacks approved female indication and does not treat male hypoactive desire — separate evaluation.

Label check: central teaching lesson: pathway fidelity before milligram trivia. Men who grasp nitric oxide dependence and nitrate logic apply it across generics and future agents.

Cross-reference sildenafil, tadalafil, and vardenafil monographs for PK tables and interaction caps. Cross-reference PDE5 generic equivalence when patients conflate regulatory substitution with cross-drug interchange.

Geriatric patients may need lower starts; Beers Criteria do not ban PDE5 outright but orthostatic fall risk matters with alpha-blockers.

Pediatric PAH sildenafil strengths must not mingle with adult ED tablets in household reconciliation. Overdose is supportive care without class antidote.

Board items should test contraindication reasoning and dose adjustment vignettes — not isolated half-life trivia.

Verify labels periodically; FDA supplements revise interaction language and dose caps after educational material publishes.

When learners ask why the pill failed attempt one, run the checklist: stimulation, meal, dose, nitrates, CYP3A4 inhibitors, licensed pharmacy — then change class.

Telehealth prescribers owe the same cardiovascular screen as clinic prescribers; shortcut history is how nitrates get missed.

Label check: morning erection history still matters after you start PDE5 therapy — loss of nocturnal rigidity while on drug may signal progressive vascular disease rather than pill failure.

Label check: partner education is under-coded but over-impactful: explaining that the tablet permits erection with stimulation, not hours of unwanted rigidity, prevents panic calls and improves adherence.

When comparing agents at the bedside, lead with half-life and food rules before IC50 slides. Patients choose logistics; prescribers who lead with bench potency create false expectations vardenafil cannot fulfill.

Penile rehabilitation after prostatectomy uses PDE5 to support corporal oxygenation during neuropraxia — efficacy is lower than in uncomplicated ED, but the pharmacology rationale is sound enough that urology protocols still include it.

Label check: vacuum erection devices and intracavernosal alprostadil remain the honest second line when optimized oral trials fail — pathway teaching should mention them so oral nonresponse does not dead-end in shame or internet counterfeits.

Board-style vignettes should test nitrate plus PDE5 interaction and meal-timing errors more often than brand-name trivia — those mistakes harm patients; trade-name recall does not.

Label supplements arrive years after curricula publish — verify interaction caps when you teach riociguat, ritonavir, and ketoconazole pairs; static slides go stale faster than faculty assume.

Label check: avanafil and other market-specific agents share class contraindications even when not covered in our monographs — teach pathway rules that transfer when formularies add new molecules.

Chronic kidney disease shifts clearance differently for each agent — when eGFR falls, pull dose tables from the specific monograph instead of guessing interval changes.

Obesity correlates with lower IIEF response across agents; lifestyle and cardiometabolic optimization belong in the same plan as tablet selection.

Hospitalists should flag outpatient PDE5 use on admission — nitrate initiation for chest pain happens fast, and last-dose time is easy to omit on transfer forms.

Recreational use of PDE5 agents without ED diagnosis still carries nitrate and interaction risk — emergency clinicians see the same hypotensive pairs as in prescribed use.

Teaching hemodynamics before brand names helps learners explain why two men on the same dose diverge — one has intact veno-occlusive trapping, one has venous leak; the pill is not the whole story.

Label check: structured follow-up at eight to twelve weeks with IIEF-5 or patient global impression prevents endless silent dose tweaks without documented outcome.

Label check: women asking whether PDE5 helps their partner's mood or desire need a clear boundary — these drugs target erectile hemodynamics, not hypoactive desire or relationship satisfaction by themselves.

Post-radiation ED onset months after therapy completion surprises patients who assumed nerves were spared — timeline counseling prevents misattribution to generic switches years later.

Intracavernosal alprostadil remains the reference second line when oral PDE5 fails after optimized trials — teach it in the same lecture as cGMP so failure does not feel like dead end.

Label check: sickle cell disease and hematologic malignancies carry higher priapism risk with any PDE5 agent — emergency instructions belong in the first prescription conversation, not the third refill.

Men on GLP-1 agonists for weight loss sometimes report improved erectile function as cardiometabolic risk falls — PDE5 dose may need downward adjustment when comorbidity control improves, not only when it worsens.

Document partner presence or absence in counseling notes when relational stress is obvious — it clarifies why the next step may be referral rather than dose change.